AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,917,430 | +44.3% | 158,280 | +65.1% | 0.00% | +33.3% |
| Q2 2023 | $2,714,755 | +15.7% | 95,860 | -6.2% | 0.00% | 0.0% |
| Q1 2023 | $2,346,294 | -49.6% | 102,146 | -38.4% | 0.00% | -40.0% |
| Q4 2022 | $4,655,608 | -43.5% | 165,798 | -43.1% | 0.01% | -50.0% |
| Q3 2022 | $8,238,000 | +34.4% | 291,291 | +5.4% | 0.01% | +42.9% |
| Q2 2022 | $6,128,000 | +161.4% | 276,419 | +243.2% | 0.01% | +250.0% |
| Q1 2022 | $2,344,000 | -50.4% | 80,543 | -44.0% | 0.00% | -50.0% |
| Q4 2021 | $4,729,000 | -27.2% | 143,866 | +2.2% | 0.00% | -33.3% |
| Q3 2021 | $6,496,000 | +451.0% | 140,754 | +558.1% | 0.01% | +500.0% |
| Q2 2021 | $1,179,000 | -73.6% | 21,388 | -75.2% | 0.00% | -75.0% |
| Q1 2021 | $4,460,000 | -44.7% | 86,358 | -53.6% | 0.00% | -42.9% |
| Q4 2020 | $8,061,000 | -31.4% | 186,030 | -44.6% | 0.01% | -41.7% |
| Q3 2020 | $11,748,000 | -15.5% | 335,670 | +29.1% | 0.01% | -29.4% |
| Q2 2020 | $13,907,000 | +17.7% | 260,044 | -21.9% | 0.02% | -10.5% |
| Q1 2020 | $11,819,000 | -26.0% | 333,103 | -0.5% | 0.02% | +5.6% |
| Q4 2019 | $15,981,000 | +467.5% | 334,674 | +285.1% | 0.02% | +350.0% |
| Q3 2019 | $2,816,000 | -15.9% | 86,915 | +29.5% | 0.00% | 0.0% |
| Q2 2019 | $3,348,000 | -76.4% | 67,112 | -68.1% | 0.00% | -77.8% |
| Q1 2019 | $14,184,000 | -4.2% | 210,313 | -34.5% | 0.02% | -10.0% |
| Q4 2018 | $14,806,000 | -10.2% | 321,095 | +50.2% | 0.02% | 0.0% |
| Q3 2018 | $16,481,000 | -8.1% | 213,712 | +0.4% | 0.02% | -13.0% |
| Q2 2018 | $17,934,000 | +10.6% | 212,915 | +7.4% | 0.02% | +4.5% |
| Q1 2018 | $16,218,000 | +646.7% | 198,315 | +422.0% | 0.02% | +633.3% |
| Q4 2017 | $2,172,000 | +351.6% | 37,988 | +317.5% | 0.00% | +200.0% |
| Q3 2016 | $481,000 | +64.2% | 9,100 | +25.9% | 0.00% | 0.0% |
| Q1 2016 | $293,000 | -62.9% | 7,227 | -40.6% | 0.00% | 0.0% |
| Q4 2015 | $790,000 | -51.6% | 12,165 | -17.2% | 0.00% | -50.0% |
| Q2 2015 | $1,633,000 | -37.5% | 14,696 | -46.9% | 0.00% | -33.3% |
| Q1 2015 | $2,612,000 | +16.6% | 27,696 | +38.5% | 0.00% | +50.0% |
| Q4 2014 | $2,240,000 | +210.2% | 20,000 | +26.9% | 0.00% | +100.0% |
| Q2 2014 | $722,000 | – | 15,762 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |